I-Mab’s Financial Report Highlights Givastomig Progress

I-Mab Adr ( (IMAB) ) has released its Q1 earnings. Here is a breakdown of the information I-Mab Adr presented to its investors.

I-Mab is a U.S.-based global biotech company specializing in the development of precision immuno-oncology agents for cancer treatment. The company has made significant strides in its lead program, givastomig, which is aimed at improving treatment for gastric cancers.

In its first-quarter 2025 financial report, I-Mab highlighted the prioritization of givastomig as its lead program, which has accelerated the Phase 1b program. The company has completed patient enrollment in the first of two Phase 1b dose expansion cohorts ahead of schedule and expects to share data in the first half of 2026.

Financially, I-Mab reported a strong cash position of $168.6 million as of March 31, 2025, which is expected to fund its operations through 2027. The company’s net loss from continuing operations was reduced to $3.2 million in the first quarter of 2025, compared to $9.4 million in the same period of 2024. This improvement is attributed to lower research and development expenses and higher interest income.

Looking forward, I-Mab is poised for continued progress with its givastomig program, supported by a substantial cash balance and streamlined operations. The company remains focused on delivering value to both patients and investors as it advances its clinical trials and strategic initiatives.